Floatz logo

Ocrevus

Clinically Isolated Syndrome

Hoffmann-La RochePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Clinically Isolated Syndrome cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
Merck KGaA, Darmstadt, Germany
Phase 4BBB
Arestin
University of Calgary
Phase 3B
PREDNISOLONE SODIUM PHOSPHATE
Lakefront Biotherapeutics NV
Phase 2CCC
Tovaxin
Opexa Therapeutics, Inc.
Phase 2CCC

Same molecule, other indications

Ocrevus is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
primary progressive multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →